Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06413498 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma

Study acronym: iMMagine-3
StatusActive, Not Recruiting
PhasePhase 3
Started2024-08-23
View on ClinicalTrials.gov ↗

Amendment history

2026-07-27
Study Status, Contacts/Locations v30
Study sites117 entries, revised
Uniwersytecki Szpital Kliniczny wim. PoznaniuJana Mikulicza-Radeckiego we Wrocławiu
2026-07-06
Study Status, Study Design, Contacts/Locations v29
Trial status changed: Recruiting → Active, Not Recruiting
Trial sites reduced: 124 → 117 locations
Enrollment targetestimated 450→confirmed 452
2026-05-05
Study Status, Contacts/Locations v28
Study sitesdetails revised at 7 of 124 sites
2026-03-25
Study Status, Contacts/Locations v27
Study sites122→124
2026-02-25
Study Status, Contacts/Locations v26
Study sites119→122
Show 25 earlier versions
2026-01-27
Study Status, Contacts/Locations v25
Study sites118→119
2026-01-09
Study Status, Contacts/Locations v24
Study sites114→118
2025-12-12
Study Status, Contacts/Locations v23
Study sites110→114
2025-11-21
Study Status, Contacts/Locations v22
Study sites107→110
2025-11-10
Study Status, Contacts/Locations v21
Study sites102→107
2025-10-17
Study Identification, Study Status, Contacts/Locations v20
Study sites99→102
2025-09-26
Study Status, Contacts/Locations v19
Study sites97→99
2025-08-14
Study Status, Contacts/Locations v18
Study sites84→97
2025-07-15
Study Status, Contacts/Locations v17
Study sites75→84
2025-06-26
Study Status, Study Description, Outcome Measures, Contacts/Locations v16
Study sites60→75
Secondary endpoints17 entries, revised
Complete Response (CR) Rate (CR/ Stringent Complete Response (sCR)) Overall Minimal Residual Disease (MRD) Negativity
Primary endpoints1 to 2 entries
Minimal Residual Disease (MRD) Complete Response (CR) Rate at 9 Months
2025-05-27
Study Status, Contacts/Locations v15
Study sites51→60
2025-05-02
Study Status, Contacts/Locations v14
Study sites42→51
2025-04-07
Study Status, Contacts/Locations v13
Study sites35→42
2025-03-17
Study Status, Contacts/Locations v12
Study sites31→35
2025-02-27
Study Status, Contacts/Locations v11
Study sites25→31
2025-02-07
Study Status, Contacts/Locations v10
Study sites16→25
2025-01-13
Study Status, Contacts/Locations v9
Study sites7→16
2024-12-17
Study Status, Contacts/Locations v8
Study sites4→7
2024-11-22
Study Status, Contacts/Locations v7
Study sites2→4
2024-10-14
Study Identification, Study Status, Oversight, Contacts/Locations v6
Study sites1→2
Study titlerevised
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants withWith Relapsed/ Refractory Multiple Myeloma
2024-09-11
Study Identification, Study Status, Oversight v5
Start dateestimated 2024-10→confirmed 2024-08-23
Study titlerevised
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants Withwith Relapsed/ Refractory Multiple Myeloma
2024-08-20
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v4
Trial statusNot Yet Recruiting→Recruiting
Study sites0→1
2024-08-05
2 amendments v2-v3
2 re-verifications since 2024-07-12, no change to tracked fields
2024-06-13
Study Status, References v1
2024-05-09
Original filing
Gilead Sciences
107 trials monitored
See 8 trials at risk
Multiple Myeloma
1,228 trials monitored
See 75 trials at risk
The goal of this study (iMMagine-3) is to compare the study drug, anitocabtagene autoleucel to standard of care therapy (SOCT) in participants with relapsed/refractory multiple myeloma who have received 1 to 3 prior lines of therapy, including an anti-CD38 monoclonal antibody and an immunomodulatory drug. The primary objective of this study is to compare the efficacy of anitocabtagene autoleucel versus SOCT in participants with RRMM.
Trial Details
NCT Number NCT06413498
Lead Sponsor Kite, A Gilead Company
Collaborators: Arcellx, Inc.
Conditions Multiple Myeloma
Enrollment 452 participants
Start Date 2024-08-23
Primary Completion 2028-07 (estimated)
Study Completion 2031-07 (estimated)
Updated on ClinicalTrials.gov 2026-07-29